Why the study?
Do ACE inhibitors and AT1-RAs reduce abnormal thirst drive in patients with end-stage renal disease or congestive heart failure?
Population
Patients with end-stage renal disease or congestive heart failure experiencing abnormal thirst drive
Design
Review
Authors
Loading...
May warrant consideration for thirst in HF or ESRD; leaves open randomized confirmation of dose and BBB effects.
Do ACE inhibitors and AT1-RAs reduce abnormal thirst drive in patients with end-stage renal disease or congestive heart failure?
ACE inhibitors and AT1-RAs may be useful in managing abnormal thirst drive in patients with heart failure or end-stage renal disease, likely as a dose-dependent class effect.
Domenic A. Sica (2001) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: